                         SEQUENCE LISTING

<110>  Pharmacyclics, Inc.
 
<120>  BIOMARKERS FOR PREDICTING RESPONSE OF DLBCL TO TREATMENT WITH 
       IBRUTINIB

<130>  25922-305.102

<160>  5     

<170>  PatentIn version 3.5

<210>  1
<211>  279
<212>  DNA
<213>  Human


<220>
<221>  misc_feature
<222>  (1)..(279)
<223>  CCL3

<400>  1
atgcaggtct ccactgctgc ccttgctgtc ctcctctgca ccatggctct ctgcaaccag       60

ttctctgcat cacttgctgc tgacacgccg accgcctgct gcttcagcta cacctcccgg      120

cagattccac agaatttcat agctgactac tttgagacga gcagccagtg ctccaagccc      180

ggtgtcatct tcctaaccaa gcgaagccgg caggtctgtg ctgaccccag tgaggagtgg      240

gtccagaaat atgtcagcga cctggagctg agtgcctga                             279


<210>  2
<211>  92
<212>  PRT
<213>  Human


<220>
<221>  MISC_FEATURE
<222>  (1)..(92)
<223>  CCL3

<400>  2

Met Gln Val Ser Thr Ala Ala Leu Ala Val Leu Leu Cys Thr Met Ala 
1               5                   10                  15      


Leu Cys Asn Gln Phe Ser Ala Ser Leu Ala Ala Asp Thr Pro Thr Ala 
            20                  25                  30          


Cys Cys Phe Ser Tyr Thr Ser Arg Gln Ile Pro Gln Asn Phe Ile Ala 
        35                  40                  45              


Asp Tyr Phe Glu Thr Ser Ser Gln Cys Ser Lys Pro Gly Val Ile Phe 
    50                  55                  60                  


Leu Thr Lys Arg Ser Arg Gln Val Cys Ala Asp Pro Ser Glu Glu Trp 
65                  70                  75                  80  


Val Gln Lys Tyr Val Ser Asp Leu Glu Leu Ser Ala 
                85                  90          


<210>  3
<211>  279
<212>  DNA
<213>  Human


<220>
<221>  misc_feature
<222>  (1)..(279)
<223>  CCL4

<400>  3
atgaagctct gcgtgactgt cctgtctctc ctcatgctag tagctgcctt ctgctctcca       60

gcgctctcag caccaatggg ctcagaccct cccaccgcct gctgcttttc ttacaccgcg      120

aggaagcttc ctcgcaactt tgtggtagat tactatgaga ccagcagcct ctgctcccag      180

ccagctgtgg tattccaaac caaaagaagc aagcaagtct gtgctgatcc cagtgaatcc      240

tgggtccagg agtacgtgta tgacctggaa ctgaactga                             279


<210>  4
<211>  92
<212>  PRT
<213>  Human


<220>
<221>  MISC_FEATURE
<222>  (1)..(92)
<223>  CCL4

<400>  4

Met Lys Leu Cys Val Thr Val Leu Ser Leu Leu Met Leu Val Ala Ala 
1               5                   10                  15      


Phe Cys Ser Pro Ala Leu Ser Ala Pro Met Gly Ser Asp Pro Pro Thr 
            20                  25                  30          


Ala Cys Cys Phe Ser Tyr Thr Ala Arg Lys Leu Pro Arg Asn Phe Val 
        35                  40                  45              


Val Asp Tyr Tyr Glu Thr Ser Ser Leu Cys Ser Gln Pro Ala Val Val 
    50                  55                  60                  


Phe Gln Thr Lys Arg Ser Lys Gln Val Cys Ala Asp Pro Ser Glu Ser 
65                  70                  75                  80  


Trp Val Gln Glu Tyr Val Tyr Asp Leu Glu Leu Asn 
                85                  90          


<210>  5
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide Substrate

<400>  5

Ala Val Leu Glu Ser Glu Glu Glu Leu Tyr Ser Ser Ala Arg Gln 
1               5                   10                  15  


